NICE guidance on dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma

Lancet Oncol. 2014 Dec;15(13):1425-1426. doi: 10.1016/S1470-2045(14)71033-2. Epub 2014 Oct 21.

Authors

Helen Tucker¹, Nwamaka Umeweni², Janet Robertson², Jane Adam²

Affiliations

¹ National Institute for Health and Care Excellence, London SW1A 2BU, UK. Electronic address: [email protected].
² National Institute for Health and Care Excellence, London SW1A 2BU, UK.

PMID: 25499274
DOI: 10.1016/S1470-2045(14)71033-2

No abstract available

Publication types

News

MeSH terms

Antineoplastic Agents / therapeutic use*
Humans
Imidazoles / therapeutic use*
Melanoma / drug therapy*
Melanoma / genetics*
Melanoma / secondary
Mutation / genetics*
Oximes / therapeutic use*
Practice Guidelines as Topic*
Prognosis
Proto-Oncogene Proteins B-raf / genetics*

Substances

Antineoplastic Agents
Imidazoles
Oximes
BRAF protein, human
Proto-Oncogene Proteins B-raf
dabrafenib